Details of the Drug

General Information of Drug (ID: DMHZV7X)

Drug Name

Golimumab

Synonyms

Simponi (TN); Golimumab (USAN/INN)

Indication

Disease Entry	ICD 11	Status	REF
Rheumatoid arthritis	FA20	Approved	[1]
Inflammatory bowel disease	DD72	Phase 2/3	[2], [3]

Drug Type

Antibody

ADMET Property

Clearance: The sytemic clearance of drug is 4.9-6.7 mL/day/kg [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 2 weeks [5]
Vd: The volume of distribution (Vd) of drug is 0.058-0.126 L/kg [4]

Cross-matching ID

DrugBank ID: DB06674
TTD ID: D09FSG

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tumor necrosis factor (TNF)	TTF8CQI	TNFA_HUMAN	Not Available	[3], [6]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Rheumatoid arthritis

ICD Disease Classification

FA20

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Tumor necrosis factor (TNF)	DTT	TNF	8.51E-01	0.05	0.27

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Golimumab

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Upadacitinib	DM32B5U	Major	Additive immunosuppressive effects by the combination of Golimumab and Upadacitinib.	Rheumatoid arthritis [FA20]	[17]
-----------

Coadministration of a Drug Treating the Disease Different from Golimumab (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Oliceridine	DM6MDCF	Moderate	Altered metabolism of Golimumab due to Oliceridine alters the formation of CYP450 enzymes.	Acute pain [MG31]	[17]
Siltuximab	DMGEATB	Major	Additive immunosuppressive effects by the combination of Golimumab and Siltuximab.	Anemia [3A00-3A9Z]	[18]
Dupilumab	DMOAD2Y	Major	Additive immunosuppressive effects by the combination of Golimumab and Dupilumab.	Atopic eczema [EA80]	[18]
Eribulin	DM1DX4Q	Major	Additive immunosuppressive effects by the combination of Golimumab and Eribulin.	Breast cancer [2C60-2C6Y]	[18]
Talazoparib	DM1KS78	Major	Additive immunosuppressive effects by the combination of Golimumab and Talazoparib.	Breast cancer [2C60-2C6Y]	[18]
LY2835219	DM93VBZ	Major	Additive immunosuppressive effects by the combination of Golimumab and LY2835219.	Breast cancer [2C60-2C6Y]	[18]
Pralatrexate	DMAO80I	Major	Additive immunosuppressive effects by the combination of Golimumab and Pralatrexate.	Breast cancer [2C60-2C6Y]	[18]
Palbociclib	DMD7L94	Major	Additive immunosuppressive effects by the combination of Golimumab and Palbociclib.	Breast cancer [2C60-2C6Y]	[18]
Cabazitaxel	DMPAZHC	Major	Additive immunosuppressive effects by the combination of Golimumab and Cabazitaxel.	Breast cancer [2C60-2C6Y]	[18]
Aflibercept	DMT3D5I	Major	Additive immunosuppressive effects by the combination of Golimumab and Aflibercept.	Colorectal cancer [2B91]	[18]
Levonorgestrel	DM1DP7T	Moderate	Altered metabolism of Golimumab due to Levonorgestrel alters the formation of CYP450 enzymes.	Contraceptive management [QA21]	[17]
Polatuzumab vedotin	DMF6Y0L	Major	Additive immunosuppressive effects by the combination of Golimumab and Polatuzumab vedotin.	Diffuse large B-cell lymphoma [2A81]	[18]
Lisocabtagene maraleucel	DMP45ME	Major	Additive immunosuppressive effects by the combination of Golimumab and Lisocabtagene maraleucel.	Diffuse large B-cell lymphoma [2A81]	[18]
Axicabtagene ciloleucel	DMYHN59	Major	Additive immunosuppressive effects by the combination of Golimumab and Axicabtagene ciloleucel.	Diffuse large B-cell lymphoma [2A81]	[18]
Oestradiol valerate and dienogest	DMZK0FQ	Moderate	Altered metabolism of Golimumab due to Oestradiol valerate and dienogest alters the formation of CYP450 enzymes.	Endometriosis [GA10]	[19]
Bay 80-6946	DMLOS5R	Major	Additive immunosuppressive effects by the combination of Golimumab and Bay 80-6946.	Follicular lymphoma [2A80]	[18]
Avapritinib	DMK2GZX	Major	Additive immunosuppressive effects by the combination of Golimumab and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[18]
177Lu-DOTATATE	DMT8GVU	Major	Additive immunosuppressive effects by the combination of Golimumab and 177Lu-DOTATATE.	Hepatitis virus infection [1E50-1E51]	[18]
Brentuximab vedotin	DMWLC57	Major	Additive immunosuppressive effects by the combination of Golimumab and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[18]
Levamlodipine	DM92S6N	Moderate	Altered metabolism of Golimumab due to Levamlodipine alters the formation of CYP450 enzymes.	Hypertension [BA00-BA04]	[17]
Brigatinib	DM7W94S	Major	Additive immunosuppressive effects by the combination of Golimumab and Brigatinib.	Lung cancer [2C25]	[18]
Lurbinectedin	DMEFRTZ	Major	Additive immunosuppressive effects by the combination of Golimumab and Lurbinectedin.	Lung cancer [2C25]	[18]
Osimertinib	DMRJLAT	Major	Additive immunosuppressive effects by the combination of Golimumab and Osimertinib.	Lung cancer [2C25]	[18]
Belimumab	DM3OBQF	Major	Additive immunosuppressive effects by the combination of Golimumab and Belimumab.	Lupus erythematosus [4A40]	[18]
Obinutuzumab	DM3BVAE	Major	Additive immunosuppressive effects by the combination of Golimumab and Obinutuzumab.	Mature B-cell leukaemia [2A82]	[18]
Idelalisib	DM602WT	Major	Additive immunosuppressive effects by the combination of Golimumab and Idelalisib.	Mature B-cell leukaemia [2A82]	[18]
GDC-0199	DMH0QKA	Major	Additive immunosuppressive effects by the combination of Golimumab and GDC-0199.	Mature B-cell leukaemia [2A82]	[18]
IPI-145	DMWA24P	Major	Additive immunosuppressive effects by the combination of Golimumab and IPI-145.	Mature B-cell leukaemia [2A82]	[18]
Acalabrutinib	DM7GCVW	Major	Additive immunosuppressive effects by the combination of Golimumab and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[18]
Blinatumomab	DMGECIJ	Major	Additive immunosuppressive effects by the combination of Golimumab and Blinatumomab.	Mature B-cell lymphoma [2A85]	[18]
Ibrutinib	DMHZCPO	Major	Additive immunosuppressive effects by the combination of Golimumab and Ibrutinib.	Mature B-cell lymphoma [2A85]	[18]
Tisagenlecleucel	DMM9BJD	Major	Additive immunosuppressive effects by the combination of Golimumab and Tisagenlecleucel.	Mature B-cell lymphoma [2A85]	[18]
Ponatinib	DMYGJQO	Major	Additive immunosuppressive effects by the combination of Golimumab and Ponatinib.	Mature B-cell lymphoma [2A85]	[18]
Carfilzomib	DM48K0X	Major	Additive immunosuppressive effects by the combination of Golimumab and Carfilzomib.	Multiple myeloma [2A83]	[18]
Selinexor	DMBD4K3	Major	Additive immunosuppressive effects by the combination of Golimumab and Selinexor.	Multiple myeloma [2A83]	[18]
Belantamab mafodotin	DMBT3AI	Major	Additive immunosuppressive effects by the combination of Golimumab and Belantamab mafodotin.	Multiple myeloma [2A83]	[18]
Daratumumab	DMKCIUZ	Major	Additive immunosuppressive effects by the combination of Golimumab and Daratumumab.	Multiple myeloma [2A83]	[18]
Tecfidera	DM2OVDT	Major	Additive immunosuppressive effects by the combination of Golimumab and Tecfidera.	Multiple sclerosis [8A40]	[18]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Golimumab and Siponimod.	Multiple sclerosis [8A40]	[20]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Golimumab and Fingolimod.	Multiple sclerosis [8A40]	[21]
Ocrelizumab	DMEZ2KH	Major	Additive immunosuppressive effects by the combination of Golimumab and Ocrelizumab.	Multiple sclerosis [8A40]	[18]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Golimumab and Ozanimod.	Multiple sclerosis [8A40]	[17]
Deflazacort	DMV0RNS	Major	Additive immunosuppressive effects by the combination of Golimumab and Deflazacort.	Muscular dystrophy [8C70]	[18]
Ruxolitinib	DM7Q98D	Major	Additive immunosuppressive effects by the combination of Golimumab and Ruxolitinib.	Myeloproliferative neoplasm [2A20]	[18]
Inebilizumab	DMI0RHA	Major	Additive immunosuppressive effects by the combination of Golimumab and Inebilizumab.	Nervous system paraneoplastic/autoimmune disorder [8E4A]	[18]
Atezolizumab	DMMF8U0	Major	Additive immunosuppressive effects by the combination of Golimumab and Atezolizumab.	Non-small cell lung cancer [2C25]	[18]
Olaparib	DM8QB1D	Major	Additive immunosuppressive effects by the combination of Golimumab and Olaparib.	Ovarian cancer [2C73]	[18]
Rucaparib	DM9PVX8	Major	Additive immunosuppressive effects by the combination of Golimumab and Rucaparib.	Ovarian cancer [2C73]	[18]
MK-4827	DMLYGH4	Major	Additive immunosuppressive effects by the combination of Golimumab and MK-4827.	Ovarian cancer [2C73]	[18]
Brodalumab	DMASDQ6	Major	Additive immunosuppressive effects by the combination of Golimumab and Brodalumab.	Psoriasis [EA90]	[18]
Tildrakizumab	DMLW9HG	Major	Additive immunosuppressive effects by the combination of Golimumab and Tildrakizumab.	Psoriasis [EA90]	[18]
Risankizumab	DMM32GT	Major	Additive immunosuppressive effects by the combination of Golimumab and Risankizumab.	Psoriasis [EA90]	[18]
Ixekizumab	DMXW92T	Major	Additive immunosuppressive effects by the combination of Golimumab and Ixekizumab.	Psoriasis [EA90]	[18]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Golimumab when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[22]
Mogamulizumab	DMISH0Z	Major	Additive immunosuppressive effects by the combination of Golimumab and Mogamulizumab.	Sezary syndrome [2B02]	[18]
LEE011	DMMX75K	Major	Additive immunosuppressive effects by the combination of Golimumab and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[18]
Pomalidomide	DMTGBAX	Major	Additive immunosuppressive effects by the combination of Golimumab and Pomalidomide.	Systemic sclerosis [4A42]	[18]
Plicamycin	DM7C8YV	Major	Additive immunosuppressive effects by the combination of Golimumab and Plicamycin.	Testicular cancer [2C80]	[18]
Belatacept	DMXLYQF	Major	Additive immunosuppressive effects by the combination of Golimumab and Belatacept.	Transplant rejection [NE84]	[18]
Durvalumab	DM4PVDY	Major	Additive immunosuppressive effects by the combination of Golimumab and Durvalumab.	Ureteral cancer [2C92]	[18]
-----------


⏷ Show the Full List of 60 DDI Information of This Drug

References

1	ClinicalTrials.gov (NCT02390700) Observational Study of Golimumab Intravenous Infusion
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6776).
3	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
4	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
7	Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Dec;16(6):1312-5.
8	Clinical pipeline report, company report or official report of AstraZeneca (2009).
9	Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol. 2004 Apr;41(2 Suppl 4):13-20.
10	Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351.
11	Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes : a potential treatment for aseptic loose... J Bone Joint Surg Am. 2001 Jul;83(7):1057-61.
12	Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
13	The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
14	Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1394-7.
15	Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008 Jun;4(6):300-9.
16	TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience... Ann Surg Oncol. 2005 Oct;12(10):825-30.
17	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
18	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
19	Product Information. Cosentyx (secukinumab). Novartis Pharmaceuticals, East Hanover, NJ.
20	Cerner Multum, Inc. "Australian Product Information.".
21	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
22	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]